|
1
|
Center MM and Jemal A: International
trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers
Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Willatt JM, Hussain HK, Adusumilli S and
Marrero JA: MR Imaging of hepatocellular carcinoma in the cirrhotic
liver: Challenges and controversies. Radiology. 247:311–330. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aitken KL and Hawkins MA: The role of
radiotherapy and chemoradiation in the management of primary liver
tumours. Clin Oncol (R Coll Radiol). 26:569–580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vauthey JN, Lauwers GY, Esnaola NF, Do KA,
Belghiti J, Mirza N, et al: Simplified staging for hepatocellular
carcinoma. J Clin Oncol. 20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klein J and Dawson LA: Hepatocellular
carcinoma radiation therapy: Review of evidence and future
opportunities. Int J Radiat Oncol Biol Phys. 87:22–32. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lock MI, Hoyer M, Bydder SA, et al: An
international survey on liver metastases radiotherapy. Acta Oncol.
51:568–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Culleton S, Jiang H, Haddad CR, et al:
Outcomes following definitive stereotactic body radiotherapy for
patients with Child-Pugh B or C hepatocellular carcinoma. Radiother
Oncol. 111:412–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng ZC, Tang ZY, Fan J, et al: A
comparison of chemoembolization combination with and without
radiotherapy for unresectable hepatocellular carcinoma. Cancer J.
10:307–316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park HC, Seong J, Tanaka M, et al:
Multidisciplinary management of nonresectable hepatocellular
carcinoma. Oncology. 81(Suppl 1): S134–S140. 2011.
|
|
12
|
Carr BI and Guerra V: Features of massive
hepatocellular carcinomas. Eur J Gastroenterol Hepatol. 26:101–108.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carr BI, Guerra V and Pancoska P:
Thrombocytopenia in relation to tumor size in patients with
hepatocellular carcinoma. Oncology. 83:339–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carr BI, Guerra V, de Giorgio M, Fagiuoli
S and Pancoska P: Small hepatocellular carcinomas and
thrombocytopenia. Oncology. 83:331–338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Péus D, Newcomb N and Hofer S: Appraisal
of the Karnofsky Performance Status and proposal of a simple
algorithmic system for its evaluation. BMC Med Inform Decis Mak.
13:722013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwartz M, Roayaie S and Konstadoulakis
M: Strategies for the management of hepatocellular carcinoma. Nat
Clin Pract Oncol. 4:424–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B, Yu J, Wang L, et al: Study of local
three-dimensional conformal radiotherapy combined with
transcatheter arterial chemoembolization for patients with stage
III hepatocellular carcinoma. Am J Clin Oncol. 26:e92–e99. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita H, Onishi H, Matsumoto Y, et al:
Local effect of stereotactic body radiotherapy for primary and
metastatic liver tumors in 130 Japanese patients. Radiat Oncol.
9:1122014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Avila MA, Berasain C, Sangro B and Prieto
J: New therapies for hepatocellular carcinoma. Oncogene.
25:3866–3884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peck-Radosavljevic M: Hepatocellular
carcinoma: The place of new medical therapies. Therap Adv
Gastroenterol. 3:259–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lawrence TS, Robertson JM, Anscher MS,
Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting
from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Purdy JA: 3D treatment planning and
intensity-modulated radiation therapy. Oncology (Williston Park).
13:155–168. 1999.PubMed/NCBI
|
|
25
|
Park HC, Seong J, Han KH, Chon CY, Moon YM
and Suh CO: Dose-response relationship in local radiotherapy for
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 54:150–155.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamada K, Izaki K, Sugimoto K, et al:
Prospective trial of combined transcatheter arterial
chemoembolization and three-dimensional conformal radiotherapy for
portal vein tumor thrombus in patients with unresectable
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 57:113–119.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoon HI, Lee IJ, Han KH and Seong J:
Improved oncologic outcomes with image-guided intensity-modulated
radiation therapy using helical tomotherapy in locally advanced
hepatocellular carcinoma. J Cancer Res Clin Oncol. 140:1595–1605.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen D, Wang R, Meng X, et al: A
comparison of liver protection among 3-D conformal radiotherapy,
intensity-modulated radiotherapy and RapidArc for hepatocellular
carcinoma. Radiat Oncol. 9:482014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao Q, Zheng R, Xie G, et al:
Late-responding normal tissue cells benefit from high-precision
radiotherapy with prolonged fraction delivery times via enhanced
autophagy. Sci Rep. 5:91192015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mornex F, Girard N, Beziat C, et al:
Feasibility and efficacy of high-dose three-dimensional-conformal
radiotherapy in cirrhotic patients with small-size hepatocellular
carcinoma non-eligible for curative therapies - mature results of
the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys.
66:1152–1158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Toramatsu C, Katoh N, Shimizu S, et al:
What is the appropriate size criterion for proton radiotherapy for
hepatocellular carcinoma? A dosimetric comparison of spot-scanning
proton therapy versus intensity-modulated radiation therapy. Radiat
Oncol. 8:482013. View Article : Google Scholar : PubMed/NCBI
|
